Cardiol Therapeutics Inc.

TSX:CRDL.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.36 +0.67%

+$0.00 today

Market cap
$164.10M
Beta
0.48
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $1.23High $2.33

Volume 0.08M

Average 0.12M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$23.85M

FY 2025 · Annual

Investing Cash Flow

-$24,484.00

FY 2025 · Annual

Financing Cash Flow

$15.54M

FY 2025 · Annual

-17.5% YoY

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.64M)(30.93M)(28.13M)(36.68M)(33.82M)
Depreciation & Amortization220.42K219.91K248.36K373.11K101.98K
Deferred Income Tax(4.92M)0(1.59M)00
Stock-Based Compensation8.5M5.01M4.17M14.28M10.7M
Change in Working Capital76.52K5.75M746.8K(931.57K)(733.34K)
Accounts Receivables(59.95K)(144.18K)67.18K(81.75K)135.43K
Inventory17.97K(4.47M)000
Accounts Payables2.39M4.47M(1.29M)(1.06M)263.69K
Other Working Capital(2.27M)5.89M679.62K214.93K(1.13M)
Other Non-Cash Items4.21M(7.27M)(627.28K)(2.1M)(105.34K)
Operating Cash Flow(23.55M)(27.22M)(25.18K)(25.06M)(23.85M)
Capital Expenditures(12.92K)(74.71K)(64)(21.29K)(24.48K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(64.25K)00
Investing Cash Flow(12.92K)(74.71K)(64.31K)(21.29K)(24.48K)
Debt Repayment(51.92K)(53.93K)(55.38K)(41.53K)(55.38K)
Common Stock Issued84.08M0021.36M16.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.35M0(55.38K)(2.47M)(477.03K)
Financing Cash Flow93.44M(53.93K)(55.38K)18.84M15.54M
Effect of Forex Changes(11.13K)2.92M762.04K1.89M(824.04K)
Net Change in Cash69.87M(24.43M)(24.54M)(4.35M)(9.16M)
Free Cash Flow(23.56M)(27.3M)(25.24K)(25.08M)(23.88M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$33.8M
+ D&A$102.0K
+ Stock-Based Comp$10.7M
+ Deferred Tax$0
- Working Capital-$733.3K
- Other Non-Cash-$105.3K
= Operating Cash Flow-$23.9M
- Capex-$24.5K
= Free Cash Flow-$23.9M

Analysis

FY2025 free cash flow is -$23.9M. FCF conversion is 70.6% of net income. Operating cash flow was -$23.9M, with capex of -$24.5K. The largest bridge item is Stock-Based Comp at $10.7M.

Recent Filings

Recent regulatory filings

No filings found.

Does CRDL.TO generate free cash flow?

Cardiol Therapeutics Inc. (CRDL.TO) generated -$23.88M of free cash flow in fiscal 2025.

How much operating cash flow does CRDL.TO produce?

Operating cash flow was -$23.85M, before capital expenditures of $24,484.00.